EUCTR2023-001144-29-Outside-EU/EEA进行中（未招募）1 期
A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Not pregnant and 1) not a woman of childbearing potential (WOCBP), or 2) a WOCBP who has not had sex with males or has had sex with males and used effective contraception since the first day of participant's last menstrual period through Day 1 and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (the rhythm method, withdrawal, and emergency contraception are not acceptable methods per the protocol).
- •Participant and participant's parent or guardian (participants aged 9-17 years only) provided written informed consent/assent.
- •Provided a primary and alternative telephone for follow-up purposes.
- •Extension Stage: participant was enrolled in the 9-19 years old group, received 3 doses of V501 in the Base Stage, and participant and participant's legally acceptable representative (if applicable) provided written informed consent/assent for the study extension.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 190
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 476
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of severe allergic reaction that required medical intervention.
- •Allergic to any vaccine component, including aluminum, yeast, or Benzonase® (nuclease).
- •Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •Currently immunocompromised or was diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition.
- •History of splenectomy.
- •Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives.
- •History of recent or ongoing alcohol or other drug abuse.
- •History of a positive test for HPV.
- •Any history of abnormal Pap test.
- •History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer.
- •Undergone hysterectomy (either vaginal or total abdominal hysterectomy).
- •Receiving or has received in the year prior to Day 1 vaccination an excluded immunosuppressive therapy. A participant will be excluded if she is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses of corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal or topical steroids are considered eligible for the study.
- •Received immune globulin product or blood-derived product within 6 months prior to Day 1 vaccination, or plans to receive any such product during the study.
- •Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
- •Received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or receipt of live vaccines within 21 days prior to Day 1 vaccination.
- •Concurrently enrolled in a clinical study of investigational agents.
- •Had >4 lifetime sexual partners.
- •Unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled.
- •An immediate family member who is investigational site or sponsor staff directly involved with this study.
- •Extension Stage: reported overdose or received non-study HPV vaccine during the Base Stage.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 12.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionEUCTR2009-016218-26-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,040
已完成
不适用
A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds)-B977 Papillomavirus as the cause of diseases classified to other chaptersPapillomavirus as the cause of diseases classified to other chaptersB977PER-141-09MERCK & CO.INC.,
进行中（未招募）
不适用
A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds). - Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 12.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionEUCTR2009-016218-26-BEMerck Sharp & Dohme (Europe) Inc.1,040
进行中（未招募）
1 期
Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV who are on Opiate Substitution Therapy.Hepatitis CEUCTR2014-000343-32-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,300
进行中（未招募）
1 期
MK-5172 in Combination with MK-8742Hepatitis CEUCTR2014-000343-32-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,200